These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 22300573)

  • 1. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.
    Wattson DA; Chen MH; Moran BJ; Dosoretz DE; Braccioforte MH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e773-9. PubMed ID: 22300573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Herlemann A; Cowan JE; Washington SL; Wong AC; Broering JM; Carroll PR; Cooperberg MR
    Eur Urol; 2024 Jun; 85(6):565-573. PubMed ID: 37858454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.
    Ashamalla H; Guirguis A; McCool K; McVorran S; Mattes M; Metzger D; Oromendia C; Ballman KV; Mokhtar B; Tchelebi M; Katsoulakis E; Rafla S
    Brachytherapy; 2017; 16(2):323-329. PubMed ID: 28139417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
    Winkfield KM; Chen MH; Dosoretz DE; Salenius SA; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e345-50. PubMed ID: 21514066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgery associated with increased survival compared to radiation in clinically localized Gleason 9-10 prostate cancer: a SEER analysis.
    Nemirovsky A; Huang H; Al Kibria GM; Naslund M; Siddiqui MM
    World J Urol; 2021 Feb; 39(2):415-423. PubMed ID: 32350585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer.
    Fankhauser CD; Parry MG; Ali A; Cowling TE; Nossiter J; Sujenthiran A; Berry B; Morris M; Aggarwal A; Payne H; van der Meulen J; Clarke NW
    Eur J Cancer; 2023 Mar; 181():70-78. PubMed ID: 36641896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial Disparity in Prostate Cancer-Specific Mortality for High-Risk Prostate Cancer: A Population-Based Study.
    Wang C; Kamrava M; King C; Steinberg ML
    Cureus; 2017 Jan; 9(1):e961. PubMed ID: 28168138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists.
    Bonde TM; Garmo H; Stattin P; Nilsson P; Gunnlaugsson A; Swanberg D; Robinson D
    Acta Oncol; 2023 Dec; 62(12):1815-1821. PubMed ID: 37850633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comorbidity and mortality results from a randomized prostate cancer screening trial.
    Crawford ED; Grubb R; Black A; Andriole GL; Chen MH; Izmirlian G; Berg CD; D'Amico AV
    J Clin Oncol; 2011 Feb; 29(4):355-61. PubMed ID: 21041707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the treatment of localized prostate cancer using supplemented cancer registry data.
    Hamilton AS; Albertsen PC; Johnson TK; Hoffman R; Morrell D; Deapen D; Penson DF
    BJU Int; 2011 Feb; 107(4):576-84. PubMed ID: 20735387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram.
    Kutikov A; Cooperberg MR; Paciorek AT; Uzzo RG; Carroll PR; Boorjian SA
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):374-9. PubMed ID: 22710832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells - Implications for systemic control.
    Wang H; Mendez L; Morton G; Loblaw A; Chung HT; Cheung P; Mesci A; Escueta V; Petchiny TN; Huang X; White SD; Downes M; Vesprini D; Liu SK
    Radiother Oncol; 2024 Feb; 191():110077. PubMed ID: 38176656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow.
    Chan K; Timotin E; Chung P; Han K; Milosevic M; Schnarr K; Sur R; Bosche J; Harnett N
    J Med Imaging Radiat Sci; 2023 Sep; 54(3):436-445. PubMed ID: 37357051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Fan LL; Xie CP; Wu YM; Gu XJ; Chen YH; Wang YJ
    Biomed Res Int; 2019; 2019():9379602. PubMed ID: 31073532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate brachytherapy in New South Wales: patterns of care study and impact of caseload on treatment quality.
    Thompson SR; Delaney GP; Gabriel GS; Izard MA; Hruby G; Jagavkar R; Bucci J; Barton MB
    J Contemp Brachytherapy; 2015 Jan; 6(4):344-9. PubMed ID: 25834577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors.
    Yamazaki H; Suzuki G; Masui K; Aibe N; Shimizu D; Kimoto T; Yamada K; Shiraishi T; Fujihara A; Okihara K; Yoshida K; Nakamura S; Okabe H
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor.
    Umezawa R; Inaba K; Nakamura S; Wakita A; Okamoto H; Tsuchida K; Kashihara T; Kobayashi K; Harada K; Takahashi K; Murakami N; Ito Y; Igaki H; Jingu K; Itami J
    Asian J Urol; 2019 Apr; 6(2):192-199. PubMed ID: 31061806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer.
    Kang HW; Jung HD; Lee JY; Kwon JK; Jeh SU; Cho KS; Ham WS; Choi YD
    J Korean Med Sci; 2018 Jan; 33(5):e36. PubMed ID: 29349945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.
    Raymond E; O'Callaghan ME; Campbell J; Vincent AD; Beckmann K; Roder D; Evans S; McNeil J; Millar J; Zalcberg J; Borg M; Moretti K
    Radiat Oncol; 2017 Mar; 12(1):56. PubMed ID: 28327203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
    Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
    Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.